PMID- 19557317
OWN - NLM
STAT- MEDLINE
DCOM- 20100618
LR  - 20211020
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Linking)
VI  - 38
IP  - 2-3
DP  - 2010 Apr
TI  - High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering 
      diseases.
PG  - 186-95
LID - 10.1007/s12016-009-8153-y [doi]
AB  - Treatment of autoimmune bullous skin diseases can often be challenging and 
      primarily consists of systemic corticosteroids and a variety of 
      immunosuppressants. Current treatment strategies are effective in most cases but 
      hampered by the side effects of long-term immunosuppressive treatment. 
      Intravenous immunoglobulin (IVIG) is one potential promising therapy for patients 
      with autoimmune bullous skin diseases, and evidence of its effectiveness and 
      safety is increasing. A number of autoimmune bullous skin diseases have been 
      identified in which IVIG treatment may be beneficial. However, experience with 
      IVIG in patients with autoimmune skin blistering disease is limited, where it is 
      recommended for patients not responding to conventional therapy. The mode of 
      action of IVIG in autoimmune diseases, including bullous diseases is far from 
      being completely understood. We here summarize the clinical evidence supporting 
      the notion, that IVIG is a promising therapeutic agent for the treatment of 
      patients with autoimmune bullous skin disease. In addition, we review the 
      proposed modes of action. In the future, randomized controlled trials are 
      necessary to better determine the efficacy and adverse effects of IVIG in the 
      treatment of autoimmune bullous skin diseases. In addition, insights into IVIG's 
      mode of action might enable us to develop novel therapeutics to overcome the 
      current shortage of IVIG.
FAU - Ishii, Norito
AU  - Ishii N
AD  - Department of Dermatology, University of Lubeck, Ratzeburger Allee 160, Lubeck 
      23562, Germany.
FAU - Hashimoto, Takashi
AU  - Hashimoto T
FAU - Zillikens, Detlef
AU  - Zillikens D
FAU - Ludwig, Ralf J
AU  - Ludwig RJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Animals
MH  - Autoantibodies/immunology
MH  - Autoimmune Diseases/*drug therapy/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Skin Diseases, Vesiculobullous/*drug therapy/immunology
RF  - 119
EDAT- 2009/06/27 09:00
MHDA- 2010/06/19 06:00
CRDT- 2009/06/27 09:00
PHST- 2009/06/27 09:00 [entrez]
PHST- 2009/06/27 09:00 [pubmed]
PHST- 2010/06/19 06:00 [medline]
AID - 10.1007/s12016-009-8153-y [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2010 Apr;38(2-3):186-95. doi: 
      10.1007/s12016-009-8153-y.